MA-REVBIO
18.1.2023 19:09:41 CET | Business Wire | Press release
RevBio, Inc., announced that it has received approval from the Italian Ministry of Health and the Ethics Committee of the University “G.D'Annunzio” of Chieti-Pescara to start a 15-patient pilot clinical trial. The primary objective of this study will be to assess the time it takes for Tetranite®, the company’s adhesive biomaterial, to regenerate bone in the mandibular and maxillary dental arches.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117006135/en/
Prior studies have demonstrated that TETRANITE® is replaced with bone via substitution as it dissolves, stimulating osteoblast cells to produce osteoid (bone precursor) which is then mineralized during the process of bone maturation. (Graphic: Business Wire)
This study will be conducted at the Center for Advanced Studies and Technology (“CAST”) of the University “G.d’Annunzio” Chieti-Pescara under the leadership of Professor Sergio Caputi, MD, DDS, who serves as the Chancellor/Provost of the University. The research team also includes Professor Maurizio Piattelli, MD, DDS, Tonino Traini, DDS, PhD, Bruna Sinjari, DDS, PhD, Gianmaria D’Addazio, DDS, PhD, and Manlio Santilli, DDS, PhD Student. This team is part of the Department of Innovative Technologies in Medicine and Dentistry where novel and cutting-edge research in dentistry is conducted.
“We are very pleased to see this study come together after much planning during the COVID-19 pandemic,” said Dr. Sinjari. “We have assembled a great research team which will be able to assess the unique osteoconductive properties of this biomaterial.”
Currently there are no products approved in Europe or the United States that are adhesive to bone and capable of bonding dental implants into place while gradually resorbing and being replaced by new, native bone. These properties have been demonstrated in prior studies, but the focus of this study will be to assess the timescale when the material is resorbed by the human body, which will help determine the length of future clinical trials necessary for obtaining commercial approval.
Dr. Paul Fugazzotto, DDS, an advisor to RevBio, and a noted lecturer, dental educator, and periodontist, introduced the company to the research team at the University of Chieti. “The design of this study will answer some important questions that will help evidence the key advantages of this biomaterial,” said Dr. Fugazzotto. “I believe this technology will be transformative in the way we place dental implants.”
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called Tetranite®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117006135/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Real Asset Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form F-4 in Connection With Proposed Business Combination7.4.2026 13:12:00 CEST | Press release
IQM Finland Oy, a global leader in deployed on-premises, full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp., a special purpose acquisition company (Nasdaq: RAAQ) (“RAAQ”), today announced the confidential submission of the draft registration statement on Form F-4 (the “Registration Statement”) filed by IQM with the U.S. Securities and Exchange Commission (“SEC”) relating to their proposed business combination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407372076/en/ IQM Quantum Computers The submission of the Registration Statement marks an important milestone toward the completion of the proposed business combination, which will result in IQM becoming a publicly traded company. The business combination remains subject to approval by RAAQ shareholders, the Registration Statement being declared effective by the SEC, and other customary closin
Reckitt Accelerates Innovation with NIQ AI Insights, reporting up to 65% faster research7.4.2026 12:30:00 CEST | Press release
Case study shows faster development and stronger-performing concepts NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new results from Reckitt’s use of NIQ BASES AI Screener, demonstrating how AI-powered insights and synthetic data are transforming innovation speed and effectiveness. The case study highlights how Reckitt has accelerated concept development while improving performance outcomes—bringing more relevant products to market, faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407069246/en/ NIQ BASES AI Screener As companies face growing pressure to innovate quickly in an increasingly complex consumer landscape, traditional research and development cycles can slow decision-making. Reckitt’s adoption of AI-powered screening reflects a broader shift toward predictive, data-driven innovation—where teams can test, refine, and optimize ideas before investing in physical development. Key Resul
Lincotek Appoints New Global General Manager for Its Medical Division7.4.2026 10:08:00 CEST | Press release
Gianluca Fioravanti to lead business as it enhances its offer to OEMs Lincotek today announced the appointment of Gianluca Fioravanti as Global General Manager of its Medical Division - a global solution provider for the orthopedic market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407710572/en/ Gianluca Fioravanti, Global GM Lincotek’s Medical Division Reporting directly to Group CEO Andrea Colombo, Fioravanti assumed the role as of April 7 and will help drive the business forward. He will lead the development and execution of the company’s global growth strategy, while ensuring its seamless operational implementation across all regions. This strategic appointment reflects Lincotek’s commitment to enhance the value it delivers to customers, strengthening its ability to serve them better. Fioravanti brings more than 25 years of international experience to the Group, having held senior leadership roles across operation
Budweiser Honors 40 Years of FIFA World Cup™ Legacy with Limited-Edition Collectible Pack and Nostalgia-Themed Platform7.4.2026 09:00:00 CEST | Press release
The iconic brand marks its return as the Official Beer Sponsor of FIFA World Cup™ with anniversary packaging, a global film, and creative billboard tributes to football’s greatest moments Today, Budweiser is celebrating 40 years as the Official Beer Sponsor of the FIFA World Cup™ with the launch of the largest limited-edition collectible pack ever – the Budweiser® FIFA World Cup™ Anniversary Pack* – bringing to life 11 bold design tributes to every tournament since 1986, and the centerpiece of a new nostalgia driven global platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407304059/en/ Budweiser® FIFA World Cup™ Anniversary Pack Throughout history, Budweiser has played an important role in some of football’s most unforgettable celebrations, from last-minute goals to trophy lifts seen around the world. These moments of “Budstalgia” [Budweiser + nostalgia] are the inspiration for the brand’s newest platform, brought
Toshiba’s Breakthrough Algorithm Harnesses Edge of Chaos to Dramatically Boost Performance of its Quantum‑Inspired Computer7.4.2026 09:00:00 CEST | Press release
~Approximately 100 times faster, will accelerate solutions for drug discovery, finance, and other complex problems~ Toshiba Corporation has developed a breakthrough algorithm that dramatically boosts the performance of the Simulated Bifurcation Machine (SBM), its proprietary quantum‑inspired combinatorial optimization computer. The new algorithm significantly improves the probability of obtaining an optimal solution or a known best solution within a limited number of trials—referred to as the success probability, a key benchmark for evaluating combinatorial optimization technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407918434/en/ Figure 1: Results demonstrating that the newly developed third‑generation SB algorithm can find the known best solution with nearly 100% probability at the edge of chaos for a fully connected 2,000‑spin Ising problem. The SBM is designed to solve large‑scale combinatorial optimizati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom